Skip to main content

Day: November 27, 2024

Brazil Potash Announces Pricing of Initial Public Offering

Written by Customer Service on . Posted in Public Companies.

MANAUS, Brazil, Nov. 26, 2024 (GLOBE NEWSWIRE) — Brazil Potash Corp. (“Brazil Potash” or the “Company”) announced today the pricing of its initial public offering (the “IPO”) of 2,000,000 of its common shares, no par value per share (“Common Shares”), at a price to the public of $15.00 per share. All of the Common Shares are being offered by the Company. The gross proceeds to the Company from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $30.0 million. In addition, the Company has granted the underwriters an option to purchase up to an additional 300,000 Common Shares, for a period of 30 days from the date of the final prospectus, to cover over-allotments, if any. The Common Shares are expected to begin trading on the NYSE...

Continue reading

BrilliA Inc Announces Pricing of Initial Public Offering

Written by Customer Service on . Posted in Public Companies.

SINGAPORE, Nov. 26, 2024 (GLOBE NEWSWIRE) — BrilliA Inc (“BRIA” or “the Company”) today announced the pricing of its initial public offering of an aggregate of 2,500,000 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by BRIA at a public offering price of $4.00 per share. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 375,000 shares of its Class A Ordinary Shares at the initial public offering price (“the Overallotment”), less underwriting discounts and commissions. The gross proceeds to BRIA from the Offering (assuming that the Overallotment is not exercised), before deducting underwriting discounts and commissions and estimated offering expenses payable by BRIA, is expected to be approximately $10,000,000. The shares are expected to...

Continue reading

Peptide Synthesis Market to Witness 13.0% CAGR by 2031 | SkyQuest Technology

Written by Customer Service on . Posted in Mergers And Acquisitions.

Demand for peptide synthesis has increased significantly in the past decade and the approval of peptide-based diagnosis therapy solution has witnessed a spike post pandemic. Westford, USA, Nov. 26, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Peptide Synthesis Market Size will attain the value of USD 1861.20 Million by 2031, with a CAGR of 13.0% during the forecast period (2024-2031). Imaging technology demand is growing substantially for accurate diagnosis of chronic diseases. The use of biosensors and biomarkers for invasive and non-invasive diagnostics is also very common. Peptide based biosensors and biomarkers are experiencing huge demand growth fueling the peptide synthesis industry. Health care costs are rising sharply in developed countries of North America and Europe. Personalized medicine is growing due to rising healthcare...

Continue reading

JOYY Reports Third Quarter 2024 Unaudited Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

SINGAPORE, Nov. 27, 2024 (GLOBE NEWSWIRE) — JOYY Inc. (NASDAQ: YY) (“JOYY” or the “Company”), a global technology company, today announced its unaudited financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights1Net revenues were US$558.7 million, compared to US$567.1 million in the corresponding period of 2023. Net income attributable to controlling interest of JOYY2 was US$60.6 million, compared to US$72.9 million in the corresponding period of 2023. Non-GAAP net income attributable to controlling interest and common shareholders of JOYY3 was US$61.2 million, compared to US$81.2 million in the corresponding period of 2023.Third Quarter 2024 Operational HighlightsAverage mobile MAUs of Bigo Live was 36.5 million, compared to 40.3 million in the corresponding period of 2023. Average mobile MAUs...

Continue reading

Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology

Written by Customer Service on . Posted in Mergers And Acquisitions.

Personalized medicines amalgams medicine with genetic technology to facilitate specific treatment unique to each patient. The demand for personalized medicines is significant for diagnosis and treatment of cancer. Westford, USA, Nov. 26, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global personalized medicines market size will reach a value of USD 1352.81 Billion by 2031, with a CAGR of 11.40% during the forecast period (2024-2031). The personalized medicines market is majorly influenced by the growing demand for innovative therapies because of the increasing global prevalence of diseases such as cancer. Furthermore, it is expected that the expansion of the personalized medicines market would benefit from a number of partnerships between researchers and industry participants. Numerous businesses are adopting this strategy...

Continue reading

Fountain Asset Corp. Announces Its Financial Results for the Quarter Ended September 30, 2024

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) — Fountain Asset Corp. (TSXV:FA) (“Fountain” or the “Company”) would like to announce its financial results for the three and nine months ended September 30, 2024 (“Q3/24”). Highlights from three months ended September 30, 2024:NAV of $5.03 million ($0.08/share) at September 30, 2024 compared to $5.73 million ($0.09/share) at June 30, 2024, representing a 11% decrease on a quarter over quarter per share basis. NAV is calculated as the value of total assets less the value of total liabilities; Net comprehensive losses of $0.71 million compared to net comprehensive losses of $0.75 million for the quarter ended September 30, 2023 (“Q3/23”); Total losses from investment activity was $0.43 million compared to losses of $0.59 million for Q3/23; Net realized gains on the sale of portfolio investments...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.